Braveheart Bio, Inc.

BRVE

priced

Analyst-verified

Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company developing therapies for hypertrophic cardiomyopathy and other cardiovascular diseases. Their lead product candidate, BHB-1893, is a cardiac myosin inhibitor for obstructive and non-obstructive HCM.

Offering

View source filing

Exchange: NASDAQ Global
Source: Finnhub
Price: $18.00
Source: Finnhub
Shares offered: 21,250,000
Source: Finnhub
Expected date: 2026-08-06
Source: Finnhub
Priced date: 2026-08-06
Source: Finnhub
Industry: Biopharmaceutical
AI-extracted
Revenue: —
Net income: —

Underwriters

Not yet disclosed.

Filings

S-1/A 2026-07-30View on EDGAR

Track BRVE

Get alerts on new filings and ask our AI analyst about this company.

Start 3-day trial